Bavarian Nordic, the biotechnology company which produces the only officially approved monkeypox vaccine could reach a capitalisation of 70 billion USD.
Bavarian Nordic is currently valued at 3.3 billion USD.
Monkeypox has turned into a global pandemic with 45 000 cases already.
Moderna, the COVID vaccine manufacturer was recently valued at 170 billion USD at its peak. And there is BioNTech and several other COVID vaccine manufacturers.
Bavarian Nordic's, being a pioneer in Monkeypox vaccine production has a huge growth potential in from of it.
Biotechnology companies are notoriously difficult to value, because they tend to overshoot the visible intrinsic value by a lot both on the upside and on the downside.
All in all, Bavarian Nordic has exciting prospects before it in the next 3-7 years, according to my humble opinion.
No comments:
Post a Comment